(Q35158942)

6 August 2017

1 reference

title

Farnesyl transferase inhibitors in myeloid malignancies (English)

1 reference

6 August 2017

Jeffrey E Lancet

1

1 reference

6 August 2017

Judith E Karp

series ordinal

2

1 reference

6 August 2017

publication date

1 September 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

123-129

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Proteins regulating Ras and its relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Function and regulation of ras.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

FLT3: receptor and ligand. Biology and potential clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Transcriptional regulation by MAP kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Raf-1 activates MAP kinase-kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Mechanisms and consequences of activation of protein kinase B/Akt

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Downstream signalling events regulated by phosphatidylinositol 3-kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Acute myelogenous leukemia and aging. Clinical interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900008-0

7 January 2021

10.1016/S0268-960X(03)00008-0

Identifiers

DOI

1 reference

6 August 2017

1 reference